ADAR2 induces the differentiation of osteosarcoma cells by editing activity on IGFBP7: new implications for therapy

Abstract

Osteosarcoma is a highly malignant bone tumor which primarily affects the juvenile population and is characterized by high rate of recurrence and metastasis. RNA editing has emerged as a key process in cancer progression. Herein, we investigated the role of RNA editing enzyme ADAR2 (Adenosine Deaminase Acting on RNA 2) in osteosarcoma. We demonstrated that ADAR2 expression increases during osteoblast differentiation and inversely correlates with the aggressiveness of osteosarcoma cells. Interestingly, the overexpression of ADAR2 in osteosarcoma cell lines reduces their tumoral properties and promotes their differentiation in osteoblast-like cells, as shown by gene expression analysis and mineralization assays. These results were also confirmed by in vivo experiments; indeed, intratibial injection of ADAR2-overexpressing osteosarcoma cells in NSG mice resulted in less aggressive tumors compared to mice injected with pEmpty or pInactive ADAR2 E/A vector-transfected cells. To elucidate the mechanisms by which ADAR2 overexpression induces osteogenic terminal differentiation of osteosarcoma cells, we performed RNA-seq analysis of Saos-2 cells and identified IGFBP7 (Insulin-like Growth Factor Binding Protein 7) as the most highly edited transcript in ADAR2-overexpressing cells. We showed that the editing activity of ADAR2 on IGFBP7 abolishes its proliferative effect on osteosarcoma cells and triggers terminal differentiation. Overall, our results indicate that ADAR2 acts as a tumor suppressor in osteosarcoma and may represent a novel therapeutic target for this aggressive pediatric tumor.

References

[1] Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol. Ther., 2016, 3: 221-243

[2] Rickel K, Fang F, Tao J. Molecular genetics of osteosarcoma. Bone, 2017, 102: 69-79

[3] Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J. Clin. Oncol., 2015, 33: 3029-3035

[4] Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem., 2010, 79: 321-349

[5] Laurencikiene J, Kallman AM, Fong N, Bentley DL, Ohman M. RNA editing and alternative splicing: the importance of co-transcriptional coordination. EMBO Rep., 2006, 7: 303-307

[6] Cesarini V, et al. . ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion. Nucleic Acids Res., 2018, 46: 2045-2059

[7] Kung CP, et al. . Correction to: evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene, 2021, 40: 2147

[8] Kung CP, Maggi LBJrWeber JD. The role of RNA editing in cancer development and metabolic disorders. Front Endocrinol. (Lausanne), 2018, 9: 762

[9] Cenci C, et al. . Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J. Biol. Chem., 2008, 283: 7251-7260

[10] Cesarini, V. et al. ADAR2 protein is associated with overall survival in gbm patients and its decrease triggers the anchorage-independent cell growth signature. Biomolecules12, 1142 (2022).

[11] Wei J, et al. . Abnormal expression of an ADAR2 alternative splicing variant in gliomas downregulates adenosine-to-inosine RNA editing. Acta Neurochir., 2014, 156: 1135-1142

[12] Chen YB, et al. . ADAR2 functions as a tumor suppressor via editing IGFBP7 in esophageal squamous cell carcinoma. Int. J. Oncol., 2017, 50: 622-630

[13] Yu S, et al. . ADAR1 ablation decreases bone mass by impairing osteoblast function in mice. Gene, 2013, 513: 101-110

[14] Patel TD, et al. . Identification of an early survival prognostic gene signature for localized osteosarcoma patients. Sci. Rep., 2024, 14 7327

[15] van Ewijk R, et al. . Prognostic value of the G2 expression signature and MYC overexpression in childhood high-grade osteosarcoma. JCO Precis Oncol., 2025, 9: e2400855

[16] Yang J, Zhang A, Luo H, Ma C. Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma. Sci. Rep., 2022, 12 1279

[17] Zhang W, et al. . Adaptive fibrogenic reprogramming of osteosarcoma stem cells promotes metastatic growth. Cell Rep., 2018, 24: 1266-1277 e1265

[18] Perbal B, et al. . Prognostic value of CCN3 in osteosarcoma. Clin. Cancer Res., 2008, 14: 701-709

[19] Pautke C, et al. . Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res., 2004, 24: 3743-3748

[20] Mohseny AB, et al. . Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab. Invest., 2011, 91: 1195-1205

[21] de The H. Differentiation therapy revisited. Nat. Rev. Cancer, 2018, 18: 117-127

[22] Rossi M, et al. . Anti-proliferative, pro-apototic and anti-migratory properties of HDAC inhibitor PXD-101 on osteosarcoma cell lines. Arch. Biochem. Biophys., 2023, 734: 109489

[23] Matsubara H, et al. . Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone]. J. Pharm. Exp. Ther., 2009, 328: 839-848

[24] Rao-Bindal K, Koshkina NV, Stewart J, Kleinerman ES. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr. Cancer Drug Targets, 2013, 13: 411-422

[25] Wang J, Li G. Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance. Oncol. Lett., 2015, 9: 940-944

[26] Miyake M, et al. . Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. Oncotarget, 2017, 8: 36099-36114

[27] Xia K, Huang X, Zhao Y, Yang I, Guo W. SERPINH1 enhances the malignancy of osteosarcoma via PI3K-Akt signaling pathway. Transl. Oncol., 2024, 39: 101802

[28] Cheng SP, et al. . Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma. Clin. Exp. Med., 2017, 17: 555-564

[29] Peppino, G. et al. Teneurins: role in cancer and potential role as diagnostic biomarkers and targets for therapy. Int. J. Mol. Sci.22, 2321 (2021).

[30] Chang, C. Y. et al. The F-actin bundler SWAP-70 promotes tumor metastasis. Life Sci. Alliance7, e202302307 (2024).

[31] Lo Giudice C, Tangaro MA, Pesole G, Picardi E. Investigating RNA editing in deep transcriptome datasets with REDItools and REDIportal. Nat. Protoc., 2020, 15: 1098-1131

[32] Picardi E, Pesole G. REDItools: high-throughput RNA editing detection made easy. Bioinformatics, 2013, 29: 1813-1814

[33] Artico, L. L. et al. IGFBP7 fuels the glycolytic metabolism in B-cell precursor acute lymphoblastic leukemia by sustaining activation of the IGF1R-Akt-GLUT1 axis. Int. J. Mol. Sci.24, 9679 (2023).

[34] Ye S, et al. . Atractylodes lancea volatile oils target ADAR2-miR-181a-5p signaling to mesenchymal stem cell chondrogenic differentiation. Anat. Rec., 2023, 306: 3006-3020

[35] Chan TW, et al. . RNA editing in cancer impacts mRNA abundance in immune response pathways. Genome Biol., 2020, 21 268

[36] Silvestris DA, et al. . Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma. Genome Biol., 2019, 20 33

[37] Song Y, et al. . RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis. J. Hepatol., 2021, 74: 135-147

[38] Guo M, et al. . Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis. Blood, 2023, 141: 3078-3090

[39] Zhang W, et al. . IGFBP7 regulates the osteogenic differentiation of bone marrow-derived mesenchymal stem cells via Wnt/beta-catenin signaling pathway. FASEB J., 2018, 32: 2280-2291

[40] Jin L, Shen F, Weinfeld M, Sergi C. Insulin growth factor binding protein 7 (IGFBP7)-related cancer and IGFBP3 and IGFBP7 crosstalk. Front. Oncol., 2020, 10: 727

[41] Evdokimova V, et al. . IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci. Signal, 2012, 5: ra92

[42] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25: 402-408

[43] Nielsen LAG, et al. . Evaluation of the proliferation marker Ki-67 in gliomas: interobserver variability and digital quantification. Diagn. Pathol., 2018, 13: 38

[44] Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics, 2018, 34: i884-i890

[45] Dobin A, et al. . STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 2013, 29: 15-21

[46] Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 2014, 30: 923-930

[47] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15 550

[48] Ritchie ME, et al. . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 2015, 43: e47

[49] Wang M, Kong L. pblat: a multithread blat algorithm speeding up aligning sequences to genomes. BMC Bioinform., 2019, 20 28

Funding

Italian Ministry of Health with “Current Research funds” PNRR-MCNT1-2023-12377671

Fondazione Umberto Veronesi (Umberto Veronesi Foundation)

Italian Ministry of Health project under the Italian Musculoskeletal Apparatus Network RAMS

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)(25110)

the Italian Ministry for University and Research (MIUR) PRIN 2022/PNRR (P20224JCNN)

RIGHTS & PERMISSIONS

The Author(s)